IL268569A - Treatment of hidradenitis suppurativa - Google Patents

Treatment of hidradenitis suppurativa

Info

Publication number
IL268569A
IL268569A IL268569A IL26856919A IL268569A IL 268569 A IL268569 A IL 268569A IL 268569 A IL268569 A IL 268569A IL 26856919 A IL26856919 A IL 26856919A IL 268569 A IL268569 A IL 268569A
Authority
IL
Israel
Prior art keywords
treatment
hidradenitis suppurativa
suppurativa
hidradenitis
Prior art date
Application number
IL268569A
Other languages
English (en)
Hebrew (he)
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Publication of IL268569A publication Critical patent/IL268569A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL268569A 2017-02-16 2019-08-07 Treatment of hidradenitis suppurativa IL268569A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762459841P 2017-02-16 2017-02-16
PCT/IB2018/000209 WO2018150265A1 (en) 2017-02-16 2018-02-16 Treatment of hidradenitis suppurativa

Publications (1)

Publication Number Publication Date
IL268569A true IL268569A (en) 2019-09-26

Family

ID=63170129

Family Applications (1)

Application Number Title Priority Date Filing Date
IL268569A IL268569A (en) 2017-02-16 2019-08-07 Treatment of hidradenitis suppurativa

Country Status (12)

Country Link
US (5) US11225517B2 (https=)
EP (1) EP3582813A4 (https=)
JP (2) JP7145162B2 (https=)
KR (1) KR20190117579A (https=)
CN (1) CN110382001A (https=)
AU (1) AU2018220862A1 (https=)
CA (1) CA3053231A1 (https=)
IL (1) IL268569A (https=)
MX (1) MX2019009798A (https=)
PH (1) PH12019501900A1 (https=)
SG (1) SG11201907159SA (https=)
WO (1) WO2018150265A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2582391B1 (en) 2010-06-18 2018-10-03 XBiotech, Inc Arthritis treatment
KR101910760B1 (ko) 2010-08-23 2018-10-22 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
TWI737000B (zh) * 2018-10-22 2021-08-21 美商美國禮來大藥廠 用於治療化膿性汗腺炎之泛-ｅｌｒ＋ｃｘｃ趨化介素抗體
MX2021010402A (es) * 2019-02-28 2021-09-14 Janssen Biotech Inc Tratamiento de la hidradenitis supurativa.
KR20220059519A (ko) 2019-09-11 2022-05-10 화이자 인코포레이티드 키나제 억제제에 의한 한선염의 치료
US20230235042A1 (en) * 2020-04-16 2023-07-27 Janssen Biotech, Inc. Treatment of hidradenitis suppurativa
US20230293544A1 (en) * 2022-03-17 2023-09-21 Pfizer Inc. Methods, dosage regimens, and compositions for treating hidradenitis

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5034316A (en) 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5407431A (en) 1989-07-11 1995-04-18 Med-Design Inc. Intravenous catheter insertion device with retractable needle
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
ES2140469T3 (es) 1992-10-14 2000-03-01 Nycomed Imaging As Composiciones y metodos terapeuticos y de diagnostico por obtencion de imagenes.
DE69427928T3 (de) 1993-03-05 2012-05-10 Bayer Healthcare Llc Humane monoklonale anti-TNF alpha Antikörper
US5959085A (en) 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9405021D0 (en) 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
GB9509620D0 (en) 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
WO1997002479A2 (en) 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
DE19943790C2 (de) 1999-09-13 2001-11-15 Ericsson Telefon Ab L M Verfahren und Vorrichtung zur Bestimmung eines Synchronisationsfehlers in einem Netzwerkknoten
US6380129B1 (en) 1999-11-02 2002-04-30 Richard J. Kraemer Enhanced materials for treatment of contamination
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US6623736B2 (en) 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
AU2007202323C1 (en) 2000-06-29 2012-04-12 Abbvie Inc. Dual specificity antibodies and methods of making and using
EP1335024A4 (en) 2000-10-19 2004-09-01 Kyowa Hakko Kogyo Kk ANTIBODIES WITH INHIBITION OF VPLF ACTIVITY
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
JP2005510524A (ja) 2001-11-16 2005-04-21 アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド ポリアミン経路の調節による神経変性障害の治療
WO2003068821A2 (en) 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
KR101317045B1 (ko) 2002-09-06 2013-10-16 암젠 인코포레이티드 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
JP4450644B2 (ja) 2003-03-03 2010-04-14 日本化薬株式会社 Ａｍｆ類を有効成分とする医薬製剤
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
KR100493102B1 (ko) 2003-06-30 2005-06-02 삼성전자주식회사 서브 하우징 스토퍼를 구비하는 휴대용 단말기의 힌지 장치
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
JP5149001B2 (ja) 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
EP1750746A1 (en) * 2004-06-04 2007-02-14 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat autoinflammatory disease
US20050276807A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
US7718674B2 (en) 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
US8603483B2 (en) 2004-12-09 2013-12-10 Janssen Biotech, Inc. Anti-integrin immunoconjugates, methods and uses
CA2617637C (en) 2005-08-02 2017-07-18 Xbiotech Inc. Diagnosis, treatment, and prevention of vascular disorders using il-1.alpha. autoantibodies
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ566971A (en) 2005-09-28 2011-06-30 Cytos Biotechnology Ag Vaccine containing a virus like particle linked with an interleukin-1 molecule
KR20110079922A (ko) 2006-04-14 2011-07-11 노파르티스 아게 안과 장애 치료를 위한 ｉｌ－1 항체의 용도
WO2007132338A2 (en) 2006-05-15 2007-11-22 Xbiotech Inc. IL-1α IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS
US20110008282A1 (en) 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
US20100040574A1 (en) 2006-05-22 2010-02-18 Xbiotech Inc. TREATMENT OF CANCER WITH ANTI-IL-1alpha ANTIBODIES
EP2032606B1 (en) 2006-05-30 2013-11-27 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
FR2902659A1 (fr) 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
EP2114443A4 (en) 2006-12-29 2011-08-10 Abbott Lab IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY
WO2009128934A1 (en) 2008-04-15 2009-10-22 Sarcode Corporation Topical lfa-1 antagonists for use in localized treatment of immune related disorders
EP2285409B1 (en) 2008-05-30 2016-04-20 XBiotech, Inc Il-1 alpha antibodies
CA2737056C (en) 2008-09-12 2018-10-30 Xbiotech Inc. Targeting pathogenic monocytes
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
EP2391652A4 (en) 2009-01-29 2013-01-02 Abbott Lab IL-1 BINDING PROTEINS
KR20120104542A (ko) 2009-10-15 2012-09-21 아보트 러보러터리즈 Ｉｌ?１ 결합 단백질
EP2575884B1 (en) * 2010-06-03 2018-07-18 AbbVie Biotechnology Ltd Uses and compositions for treatment of hidradenitis suppurativa (hs)
EP2582391B1 (en) 2010-06-18 2018-10-03 XBiotech, Inc Arthritis treatment
KR101910760B1 (ko) 2010-08-23 2018-10-22 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
CN103328511B (zh) 2010-09-10 2016-01-20 埃派斯进有限公司 抗-IL-1β抗体及其使用方法
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
ES2600616T3 (es) * 2011-03-14 2017-02-10 Phlogo Aps Antagonistas del receptor de la interleucina-1
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
DK2694107T3 (en) 2011-04-01 2018-12-10 Xbiotech Inc TREATMENT OF DERMATOLOGICAL DISORDERS
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN108404127B (zh) 2011-09-23 2025-12-12 埃克斯生物科技公司 恶病质治疗
US20130195877A1 (en) 2012-01-31 2013-08-01 Xbiotech, Inc. Treatment of cachexia by targeting interleukin-1 beta
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
CN104684581A (zh) * 2012-10-04 2015-06-03 埃克斯生物科技公司 精神病症的治疗
JP6460993B2 (ja) 2012-10-04 2019-01-30 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 血管疾患及びその合併症の処置
JP6371758B2 (ja) * 2013-03-12 2018-08-08 全薬工業株式会社 抗ブドウ球菌抗体、その製造方法並びにその使用
US20150024031A1 (en) 2013-07-17 2015-01-22 Baxter International Inc. Methods And Compositions For Reducing Pain, Inflammation, And/Or Immunological Reactions Associated With Parenterally Administering A Primary Therapeutic Agent
WO2015187779A1 (en) 2014-06-03 2015-12-10 Xbiotech, Inc. Compositions and methods for treating and preventing staphylococcus aureus infections

Also Published As

Publication number Publication date
PH12019501900A1 (en) 2019-10-21
MX2019009798A (es) 2020-01-30
SG11201907159SA (en) 2019-09-27
AU2018220862A1 (en) 2019-08-29
US11225517B2 (en) 2022-01-18
US20190389946A1 (en) 2019-12-26
WO2018150265A1 (en) 2018-08-23
US20220127353A1 (en) 2022-04-28
KR20190117579A (ko) 2019-10-16
RU2019127384A (ru) 2021-03-16
EP3582813A1 (en) 2019-12-25
CA3053231A1 (en) 2018-08-23
CN110382001A (zh) 2019-10-25
US20180230211A1 (en) 2018-08-16
JP2022188083A (ja) 2022-12-20
RU2019127384A3 (https=) 2021-06-04
JP7145162B2 (ja) 2022-09-30
US20240025989A1 (en) 2024-01-25
JP2020507587A (ja) 2020-03-12
EP3582813A4 (en) 2020-12-30
US20210179704A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
IL277538A (en) Use of JAK inhibitors to treat hidradenitis suppurativa
ZA202006746B (en) Methods of treatment
IL268569A (en) Treatment of hidradenitis suppurativa
IL275482A (en) Asketamine for the treatment of depression
IL259110A (en) Treatment of osteoarthritis (osteoarthritis)
IL274459A (en) Treatment of hidradenitis suppurativa with IL-17 antagonists
EP3228302A4 (en) Hair deformation treatment agent
ZA201907401B (en) Treatment of adipocytes
EP3228303A4 (en) Hair deformation treatment agent
ZA201705847B (en) Treatment of pain
EP3228300A4 (en) Hair deformation treatment agent
PL3448340T3 (pl) Pomocniczy element aplikacyjny do opatrywania ran
IL250594B (en) The composition for the treatment of nerve diseases and/or neuropathic pain
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
PL3713572T3 (pl) Leczenie tachykardii
PT3187160T (pt) Ligadura de compressão para o tratamento de linfedemas
IL254793A0 (en) A compound for the treatment of neuropathic diseases and/or neuropathic pain
EP3271017A4 (en) Treatment of skin conditions
PT3280407T (pt) Utilização de derivados de isotiocianato como moduladores de dor periférica e neuropática
HK40019205A (en) Treatment of hidradenitis suppurativa
HK40027562A (en) Treating hidradenitis suppurativa with il-17 antagonists
PL3423035T3 (pl) Wodny roztwór burlulipazy zawierający jony wapnia
HK40006632A (en) Treatment of pain
AU2015900943A0 (en) Treatment of skin conditions
AU2016901912A0 (en) Treatment of Pain